CM
RLAY icon

Caption Management’s Relay Therapeutics RLAY Stock Holding History

Caption Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.5M Buy
1,060,000
+559,900
+112% +$5.01M 0.06% 317
2025
Q4 		$4.23M Buy
+500,100
New +$3.57M 0.03% 572
2024
Q4 		– Sell
-18,500
Closed -$131K – 1781
2024
Q3 		$131K Buy
+18,500
New +$138K ﹤0.01% 1106

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Caption Management's RLAY Position: Q4 2024 in Review

Caption Management sold out of Relay Therapeutics (RLAY) in Q4 2024, closing a stake of 7,000 shares — an estimated $49.6K sold.

Caption Management first reported a position in RLAY in Q1 2022 and held it in 3 quarters. The position peaked at $420K in Q1 2023. 199 funds tracked by Wall St. Rank hold RLAY as of Q4 2024.

  • Caption Management reported no remaining Relay Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Caption Management sold 7,000 Relay Therapeutics shares in Q4 2024, an estimated $49.6K.
  • Caption Management first reported a position in Relay Therapeutics in Q1 2022 and held it in 3 quarters.
  • Caption Management's Relay Therapeutics position peaked at $420K in Q1 2023.
  • 199 funds tracked by Wall St. Rank held Relay Therapeutics as of Q4 2024.

Based on Caption Management's 13F filing for Q4 2024, filed 14 Feb 2025.